webinar register page

Highlighting RenovoRx's RenovoTAMP™ therapy platform with presenters Dr. Ramtin Agah, RenovoRx’s Chief Medical Officer, Dr. Michael Pishvaian, a Principal Investigator for the Company’s Phase 3 TIGeR-PaC trial, and Shaun Bagai, CEO

Topic

Facing Today’s Challenges in Pancreatic Cancer Treatment: Understanding RenovoRx’s Trans-Arterial Micro-Perfusion Therapy Platform

Description

You are invited to our webcast on Thursday, June 21st at 8:00 a.m. ET. Speakers include Dr. Michael Pishvaian, who also serves as Study Chair for the Phase 3 TIGeR-PaC clinical trial, and RenovoRx's CEO, Shaun Bagai. The presentation will address currently available treatment options for pancreatic cancer and why they can fall short of providing an effective solution in fighting this deadly disease, and how the RenovoRx therapy platform re-envisions therapy for this and other difficult-to-treat cancers. Additionally, the presentation will cover the Company’s plan for expanding the utility of its innovative therapy platform and its anticipated milestones for the remainder of the year.The event will include a Q&A session. Learn more about us at https://www.renovorx.com/

Time

Jun 21, 2022 08:00 AM in Eastern Time (US and Canada)

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: .

Time Zone:

Your Information
Send to
Message preview	Hi there, You are invited to a Zoom webinar. When: Jun 21, 2022 08:00 AM Eastern Time (US and Canada) Topic: Facing Today’s Challenges in Pancreatic Cancer Treatment: Understanding RenovoRx’s Trans-Arterial Micro-Perfusion Therapy Platform Register in advance for this webinar: https://us06web.zoom.us/webinar/register/WN_FkHV4w1NQXGwCU4rW5LWNQ After registering, you will receive a confirmation email containing information about joining the webinar. ---------- Webinar Speakers Shaun Bagai (RenovoRx CEO @RenovoRx) Mr. Bagai has served as our Chief Executive Officer and director since June 2014. Prior to joining us, Mr. Bagai led Global Market Development for HeartFlow, Inc. from 2011 to 2014, which included directing Japanese market research, regulatory/payer collaboration, and Key Opinion Leader development to create value resulting in a company investment to form HeartFlow-Japan. During his tenure at HeartFlow, he successfully orchestrated their largest clinical trial to date and contracted HeartFlow’s first global customers. In addition, Mr. Bagai has launched innovative technologies into regional and global marketplaces in both large corporations and growth-phase novel technology companies. He was instrumental in developing the European market for renal denervation for the treatment of hypertension leading to the acquisition of the first renal denervation company — Ardian, Inc. by Medtronic in 2011. Mike Pishvaian, M.D., PhD (Principal Investigator for RenovoRx’s Phase 3 TIGeR-PaC trial, @RenovoRx) Dr. Pishvaian is Associate Professor in the Department of Oncology, and Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs at the NCR Kimmel Cancer Center at Sibley Memorial Hospital at Johns Hopkins University School of Medicine. Dr. Pishvaian is a translational oncologist, focused on providing novel therapy for patients, particularly in the areas of pancreatic cancer and refractory colorectal cancer. His work has been focused in the area of precision medicine, with a special focus on therapy targeted towards homologous recombination DNA repair deficient tumors, and Dr. Pishvaian is a Co-investigator on an NIH RO1 to study mechanisms of resistance to PARP inhibitor-based therapy.

webinar register page

Share via Email

Switch Time Zone

Upcoming Meetings